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Abstract 
Glucocorticoids are known to increase production of the anti-inflammatory cytokine IL-10, 
and this action is associated with their clinical efficacy in asthmatics. However, glucocorticoids 
also enhance the synthesis of IL-17A by peripheral blood mononuclear cells, which in excess 
is associated with increased asthma severity and glucocorticoid-refractory disease. Here we 
show that the glucocorticoid dexamethasone significantly increased IL-10 production by 
human memory CD4+ T cells from healthy donors, as assessed by intracellular cytokine 
staining. In addition, dexamethasone increased production of IL-17A, IL-17F and IL-22, with 
the most striking enhancement in cells co-producing Th17-associated cytokines together with 
IL-10. Of note, an increase in IFN+IL-10+ cells was also observed despite overall 
downregulation of IFN production. These dexamethasone-driven IL-10+ and predominantly 
the IL-17+IL-10+ double-producing cells were markedly refractory to the inhibitory effect of 
dexamethasone on proliferation and IL-2R expression, which facilitated their preferential IL-
2-dependent expansion. Whilst lower concentrations of exogenous IL-2 promoted IL-10+ cells 
co-producing pro-inflammatory cytokines, higher IL-2 doses, both alone and in combination 
with dexamethasone increased the proportion of single IL-10+ T cells. Thus, glucocorticoid-
induced IL-10 is only accompanied by an increase of IL-17 in a low IL-2 setting, which is 
nevertheless likely to be protective owing to the induction of regulatory IL-17+IL-10+ co-
producing cells. These findings open new avenues of investigation with respect to the role of 
IL-2 in glucocorticoid responsiveness that have potential implications for optimising the 
benefit-risk ratio of glucocorticoids in the clinic.  
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Introduction 
Glucocorticoids are a class of lipophilic steroid hormones that are synthesised endogenously 
by the adrenal cortex. They can bind to the glucocorticoid receptor (GR), which is expressed 
by most nucleated cells, and trigger a broad range of effects via transactivation and 
transrepression, in addition to other GR-independent actions. Their actions are pleiotropic, 
affecting various physiological processes including development, metabolism and 
inflammation, and as such, synthetic glucocorticoids have been used in the clinic since 1948 
(1). Glucocorticoids remain the most important anti-inflammatory pharmacotherapy in modern 
medicine, despite their untoward side-effects. Their anti-inflammatory properties result from 
their transrepression of pro-inflammatory genes such as interleukin (IL)-1β and IL-4, 
transactivation of anti-inflammatory genes and upregulation of the frequency and activity of 
regulatory T cells (Tregs) (2). In vivo glucocorticoids have been shown to increase serum levels 
of the anti-inflammatory cytokine IL-10 (3) as well as the synthesis of IL-10 by cells locally in 
the airways (4). Furthermore, the synthetic glucocorticoid dexamethasone enhances the 
concentration of IL-10 in cultures of peripheral blood mononuclear cells (PBMCs), CD4+ and 
CD8+ T cells isolated from healthy humans in vitro (5-8). 
 
The importance of glucocorticoid-induced IL-10 is highlighted by studies in patients with 
severe steroid-resistant (SR) asthma, who represent a profound clinical challenge for disease 
management. SR asthma patients have a defect in the dexamethasone-driven IL-10 response 
(6, 9, 10) and heightened levels of IL-17A; indeed levels of IL-17A inversely correlate with 
lung function (11) and are significantly elevated in the peripheral blood (6, 7, 12), sputum (13), 
serum (14, 15) and bronchial alveolar lining fluid (16, 17) of patients with severe asthma, with 
the greatest levels observed in patients with SR disease (7). Levels of IL-17A are also elevated 
in mouse models of airway hyperresponsiveness where Th17 cells drive pathology (18, 19).  
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Th17 cells are critical for protecting against mucosal and fungal infections, however they have 
also been implicated in various immune-mediated diseases (20). More specifically, cells that 
differentiate in the presence of IL-23 and TGF-β3 to co-express Th1- and Th17-associated 
molecules have been shown to drive experimental autoimmune encephalomyelitis in mice (21, 
22). Ramesh et al. showed human peripheral blood CD4+ T cells cultured with IL-23 produced 
IL-17A, IL-17F, IL-22 and IFN-γ but not IL-10 (23). However distinct Th17 phenotypes exist, 
for example Zielinski et al. observed Candida albicans-specific human CD4+ T cells producing 
IL-17A and IFN-γ but not IL-10, and Staphylococcus aureus-specific cells that in contrast 
could produce IL-10 (24). Functionally, Th17 cells that co-produce IL-10 have been shown to 
restrain Th17-cell mediated pathology (21, 25-27)  
 
In order to better understand these seemingly opposing effects of glucocorticoids on the 
induction of IL-10 and IL-17A, this study sought to characterise the cellular source of 
glucocorticoid-driven IL-10 and investigate its co-expression with other cytokines, based on 
emerging data of functionally distinct Th17 subsets. We set out to dissect the mechanism for 
induction of IL-10 versus IL-17 in T cells, which are critical targets in inflammatory tissues, 
such as the airways in asthma. This study identifies that glucocorticoids enhance the proportion 
of memory CD4+ T cells that co-produce IL-17+IL-10+, which is reflective of a less 
inflammatory, protective Th17 phenotype. Notably, addition of higher dose exogenous IL-2 
skews this response towards a single IL-10-producing phenotype, which has potential 
implications for generating more targeted therapeutics.   
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Materials and Methods 
Cell isolation and culture 
Ethical approval was granted by London Bridge National Research Ethics Service Ethics 
Committee (REC 09/H0804/77 and REC 14/LO/16990) and HTA license number 12650 at the 
Francis Crick Institute, and full written informed consent obtained from all donors. Peripheral 
venous blood was collected from non-asthmatic male and female healthy adults into syringes 
containing sodium citrate (10:1). Peripheral blood mononuclear cells (PBMCs) isolated using 
Lymphoprep as previously described (8). CD45RO+ memory CD4+ T cells were purified by 
negative selection (Miltenyi Biotec; Bisley, UK; >97% CD4+CD45RO+). Cells were re-
suspended at a concentration of 1x106 cells/ml in RPMI 1640 growth medium containing 10% 
FBS, 2 mM L-glutamine and 50 µg/ml gentamycin.  
 
0.5x106 cells were stimulated with 1 μg/ml plate-bound anti-CD3 (clone OKT-3) and 50 IU/ml 
rhIL-2 (Eurocetus, Harefield, UK) for 5 days unless otherwise stated in a 48-well plate at 37°C 
(5% CO2). On day 3, half of the supernatant was removed and replaced with full media 
supplemented with rhIL-2. 100 nM dexamethasone (Sigma-Aldrich; Gillingham, UK) or 
0.01% ethanol vehicle control was added to the cell cultures where indicated. 10 μg/ml anti-
IL-2 (aIL-2; clone 5334; R&D Systems) was added on days 0 and 3 where indicated.  
 
Cell proliferation 
Prior to culture cells were labeled with 1 μM CellTrace Violet as per the manufacturer’s 
instructions (ThermoFisher). Cell proliferation was assessed by loss of fluorescence intensity 
on an NxT Attune (ThermoFisher) or Fortessa (BD Biosciences). 
 
Surface Staining 
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Cells were harvested and washed in 2% FCS-PBS prior to performing viability (Zombie 
Violet/Aqua viability dye (Life Technologies)) and surface staining on ice in the dark for 30 
minutes. The following antibodies were used for cell surface phenotyping: CD4-PerCPCy5.5, 
CD45RA-APCCy7, CD45RO-PECy7 (clones OKT4, HI100 and UCHL1 respectively; 
Biolegend), CD3-V500 CD25-APCH7 (clones SP34-2 and M-A251 respectively; BD 
Biosciences), CD122-FITC (TU27; eBiosciences). Cells were washed a further two times in 
2% FCS-PBS and then fluorescence assessed using an NxT Attune or Fortessa. 
 
Intracellular staining 
Human cells were stimulated with 5 ng/ml PMA (phorbol-12-myristate-13-acetate) and 500 
ng/ml Iononomycin (Sigma Aldrich) for 4 hours at 37°C, with 2 µM Monensin added the final 
3 hours. Cells were surface stained on ice with the relevant markers and aqua zombie viability 
dye (BioLegend) for 30 minutes before fixing and permeabilising using BD FixPerm kit as per 
the manufacturer’s instructions. The following antibodies were used to stain intracellular 
molecules: IL-22-PECy7 (22URTI), IL-22-PE (22URTI) IL-4-PECy7 (8D4-8), IL-17A-APC 
(eBio64Dec17), IL-17F-aF488 (Poly5166) and IL-2-PerCPCy5.5 (MQ1-17H12), all from 
eBiosciences; IFN--FITC (4S.B3) and IL-10-PE (JEs3-9D7) from BD Biosciences. Cells were 
washed a further two times in 2% FCS-PBS and then fluorescence assessed using an NxT 
Attune or Fortessa. 
 
Phospho-STAT5 flow cytometry 
Cells were rested in full media for 2 hours and then stimulated with 5ng/ml rhIL-2 for 30 
minutes. Samples were then surface stained and fixed prior to re-suspending BD Phosflow 
Perm Buffer III. Samples were incubated in Perm Buffer III on ice for 30 minutes and then 
washed twice in Perm Buffer III before staining with the phospho-STAT5 antibody (Alexa 
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Fluor 488; 47/Stat5 (pY694); BD Biosciences) for a further 30 minutes on ice. Cells were 
washed a further two times in 2% FCS-PBS and then fluorescence assessed using an NxT 
Attune or Fortessa. 
 
Data analysis 
Flow cytometry data were analysed using FlowJo (Treestar Inc.; version 10). Singlet events 
(based on both forward and side scatter area and height comparison) and viable (Zombie Aqua 
negative) cells were selected prior to analysis. Cumulative data analysis was performed in 
Graphpad Prism version 7.00 for Mac OS X (Graphpad Software Inc., San Diego, USA). After 
assessing for a Gaussian distribution, an appropriate statistical test was performed as described 
in the figure legends at the 95% confidence level. Data are shown as mean +/- standard error 
of the mean (SEM).  
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Results 
Dexamethasone increases production of IL-10 by human memory CD4+ T cells  
We have previously shown that the glucocorticoid dexamethasone increases the concentration 
of IL-10 in the supernatants of anti-CD3/IL-2-stimulated CD8-depleted PBMC, CD4+ T cell 
and CD8+ T cell cultures (5-8). To characterise which T cell subpopulation showed the greatest 
induction of IL-10 expression by dexamethasone, PBMCs were stimulated with anti-CD3 and 
IL-2 T cell stimulation in the absence or presence of 10-7M dexamethasone. Dexamethasone 
increased the frequency of IL-10-producing cells to the greatest extent in the CD45RO+ 
memory compartment of CD4+ PBMCs following 5 days stimulation as assessed by 
intracellular cytokine staining (Figure 1A and B; Supplementary Figure 1). Consistent with 
this, in pure memory CD4+ T cell cultures a greater frequency of cells expressed IL-10 and this 
was dose-dependently upregulated by dexamethasone (Figure 1C).  
 
Dexamethasone enhances production of IL-10 and IL-17A, but not IFN or IL-4  
The kinetics of the dexamethasone-driven IL-10 response was next investigated directly in 
memory CD4+ T cells stimulated over a 6-day culture period (Figure 2). In the absence of 
dexamethasone, the frequency of IL-10-producing cells reduced over time. In contrast, addition 
of 10-7M dexamethasone significantly increased the frequency of IL-10+ cells by day 5, 
although not at earlier time points. The proportion of IL-17A+ cells gradually increased with 
time and dexamethasone significantly, albeit more modestly, further enhanced the frequency 
of IL-17A+ T cells at days 5 and 6 of culture (Figure 2A). In contrast, expression of IFN, IL-
4 and IL-2 was reduced or unaltered by dexamethasone throughout the culture (Figure 2A and 
B). These findings are in keeping with our previous findings (6, 7, 12) and further demonstrate 
that memory CD4+ T cells are the cellular source of both IL-10 and IL-17 following 
dexamethasone treatment. 
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Dexamethasone induces co-production of IL-10 with multiple pro-inflammatory 
cytokines  
IL-10+CD4+ T cells can co-produce multiple other pro-inflammatory cytokines in a 
heterogeneous manner (28), including IL-17A (21, 24-27). We therefore investigated the effect 
of dexamethasone on other Th17-associated cytokines, as well as the co-production of 
cytokines with IL-10 by memory CD4+ T cells. Dexamethasone enriched the proportion of 
memory CD4+ T cells producing the Th17 family members IL-17F and IL-22 (Figure 3A and 
B; Supplementary Figure 2A). The average fold change in IL-17A, IL-17F and IL-22 
expression was 1.9-, 4.3- and 1.4-fold respectively, and that of IL-10+ cells was 4.9-fold, 
relative to the vehicle control (Supplementary Figure 2B). Notably greater fold increases were 
consistently observed in cells co-producing IL-10 together with Th17-associated cytokines, as 
compared to their IL-10- counterparts (Supplementary Figure 2B). Dexamethasone 
significantly reduced the frequency of IFN+ cells that did not co-produce IL-10 but induced a 
7.5-fold increase in the proportion of IFN+IL-10+ memory CD4+ T cells, resulting in no change 
in the overall proportion of IFN+ memory CD4+ T cells. A similar trend was observed for 
production of IL-4 and IL-2 by dexamethasone-treated memory CD4+ T cells, with an enhanced 
proportion of cells co-producing IL-10 in contrast to a reduced frequency of IL-10- cells.  
 
Since it has been reported that inflammatory Th17 cells may co-produce inflammatory 
cytokines such as IFN(21-23), the dexamethasone-stimulated cells analysed for IL-10 and IL-
17A production were further investigated for co-production of IL-17F (yellow); IL-22 (red); 
IFN (blue); IL-4 (green); and IL-2 (orange) (Figure 3C). As predicted, IL-17F (yellow) was 
predominantly produced by IL-17A+ cells, irrespective of whether they were IL-10- or IL-10+.  
Although IL-22+ cells (red) were present in both the IL-10+ and IL-10- populations, most did 
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not co-produce IL-17A. The majority of IFN+ (blue) or IL-4+ (green) cells did not co-produce 
IL-17A but many co-expressed IL-10+. IL-2+ (orange) cells were predominantly negative for 
IL-17A and IL-10 (Figure 3C). Therefore, dexamethasone dominantly drives the production of 
IL-10 across all memory CD4+ T cell subsets, excluding those producing IL-2. Notably, the 
dexamethasone-stimulated IL-17A-producing cells were predominantly negative for IFN, IL-
4 and IL-2, although a large proportion co-produced IL-10, which is indicative of a non-
pathogenic Th17 phenotype (25-27, 29). 
 
IL-10+ cells are refractory to the suppressive effects of dexamethasone on cell 
proliferation 
To investigate the mechanisms driving the enrichment of IL-10+ cells within dexamethasone-
treated memory CD4+ T cell cultures, cytokine expression was assessed in relation to cell 
proliferation. Memory CD4+ T cells were labelled with the fluorescent dye CellTrace Violet 
prior to stimulation in the presence or absence of dexamethasone. IL-10 and IL-17A were 
produced predominantly by cells that had undergone multiple rounds of cell division (Figure 
4A) and were enhanced in the presence of dexamethasone (Figure 4A and B). In contrast IFN 
and IL-4 production was seen in both dividing and non-dividing cells, but their frequency was 
not altered by dexamethasone. IL-2 was produced primarily by the undivided population and 
was decreased by dexamethasone (Figure 4 and B).  
 
Glucocorticoids have been repeatedly shown to dampen T cell proliferation (30), which we 
now show for total memory CD4+ T cells (“All cells” Figure 4C and D). However, cells 
producing IL-10 and/or IL-17A were refractory to this suppressive effect of dexamethasone on 
cell proliferation (Figure 4C and D). This contrasts with the proliferation of IFN+, IL-4+ and 
IL-2+ cells which was significantly reduced in dexamethasone-treated cultures (Figure 4C and 
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D). Notably the proliferation of all IL-10+ memory CD4+ T cells, regardless of whether they 
co-produced IFN, IL-4 or IL-2, was not suppressed by dexamethasone, in marked contrast to 
their IL-10- counterparts (Figure 4C and D). These data show that IL-17A+ and IL-10+ cells are 
markedly refractory to the anti-proliferative effects of dexamethasone. 
 
IL-10+ memory CD4+ T cells are resistant to down-regulation of the IL-2 receptor by 
dexamethasone 
IL-2 plays a central role in supporting the proliferation of T cells (31, 32) and its production is 
known to be inhibited by dexamethasone (33). Therefore, the contribution of this pathway to 
the observed differential effect of dexamethasone on IL-10+ versus IL-10- cells was next 
investigated. Cell surface expression of IL-2 receptor components CD25 (high affinity IL-2R) 
and CD122 (IL-2R) increased upon stimulation over time and this increase was inhibited by 
dexamethasone (Figure 5A and B). Dexamethasone-treated memory CD4+ T cells also showed 
lower amounts of downstream STAT5 phosphorylation as compared to vehicle control. The 
cells that had upregulated CD25 proceeded into cell division regardless of the action of 
dexamethasone (Figure 5C). Moreover, the percentage of CD25+ cells was higher on the IL-
10+ cells as compared to IL-10- cells, suggesting that IL-10+ cells are selectively resistant to 
modulation of CD25 by dexamethasone (Figure 5D). This provides a possible explanation for 
our findings that IL-10+ memory CD4+ T cells continue to proliferate in the presence of 
dexamethasone.  
 
High dose IL-2 maintains dexamethasone-induced IL-10 whilst inhibiting IL-17A in 
memory CD4+ T cells  
In the experiments described above 50 IU/ml rhIL-2 was routinely added to all cultures. To 
further investigate the resistance of IL-10+ cells to downregulation of the IL-2 receptor CD25 
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and continued proliferation in the presence of dexamethasone, we investigated the contribution 
of IL-2 to this process. Dexamethasone induction of IL-10 required the addition of rhIL-2, with 
no dexamethasone-mediated enhancement of IL-10 observed in the presence of anti-IL-2 
neutralising monoclonal antibody (mAb) due to its suppressive effect on proliferation (Figure 
6A and B).  In the absence of dexamethasone, addition of anti-IL-2 mAb to the cultures led to 
a consistent decrease in the frequency of cells producing IL-10 and all effector cytokines 
measured, with the exception of IL-2 which was shown to be increased as compared to the 
vehicle control without IL-2 intervention (Figure 6A; data not shown for IFN and IL-4). 
Conversely, increasing concentrations of rhIL-2 in the absence of dexamethasone dose-
dependently increased the frequency of IL-10-producing cells, whilst reducing that of IL-2-
producing cells. Nevertheless, at all concentrations of IL-2 studied, 50 – 1000 IU/ml, the 
addition of dexamethasone further enhanced the frequency of memory CD4+ T cells producing 
IL-10 without affecting levels of IL-2 (Figure 6A and B). 
 
Enhancement of the frequency of IL-17A+ T cells by dexamethasone was also IL-2-dependent, 
as it was not observed either in the presence of anti-IL-2 or without addition of exogenous IL-
2 to the cultures (Figure 6A). In contrast to IL-10, however, the capacity of dexamethasone to 
increase IL-17A production was only seen at the lower concentration of IL-2 studied and was 
inhibited at the higher concentrations of IL-2 (500-1,000 U/ml). Therefore higher-dose rhIL-2 
importantly maintained the elevated IL-10 response to dexamethasone, whilst constraining the 
inductive effect of dexamethasone on IL-17A. As observed for IL-17A, low-dose, but not 
higher concentrations of rhIL-2 were required for dexamethasone to enhance the frequency of 
memory CD4+ T cells co-producing IL-10 and IL-17A (Figure 6A). Furthermore, when higher 
doses of rhIL-2 was added to the cultures, dexamethasone increased IL-10 production by both 
dividing and un-dividing cells (Figure 6B and C). Thus, our data suggest that IL-2 can 
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independently upregulate IL-10 in the absence of dexamethasone, and that dexamethasone 
further increases IL-10 over-and-above the effect of IL-2. Notably, the combination of 
glucocorticoids and a higher dose of IL-2 promoted an IL-10+ memory CD4+ T cell population 
with minimal co-production of pro-inflammatory cytokines.  
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Discussion 
Glucocorticoids are the cornerstone of treatment for patients with asthma and many other 
inflammatory conditions, and their clinical efficacy is linked in part to their capacity to induce 
synthesis of the anti-inflammatory cytokine IL-10 (9). To further expand our understanding of 
glucocorticoid action, we used cells from healthy individuals who respond to dexamethasone 
by increases in IL-10 and IL-17A but are devoid of any confounding asthma-associated defects 
(7). We show that a major source of glucocorticoid-induced IL-10 synthesis is CD4+ memory 
T cells, which are abundant in tissues such as the lung (34). Glucocorticoids enhanced the 
frequency of IL-10-expressing T cells, an effect that was particularly marked in T cells co-
expressing IL-10 along with a range of effector, including Th17-associated cytokines. The 
glucocorticoid dexamethasone concurrently increased the frequency of cells producing IL-
17A, resulting largely from enrichment in the frequency of IL-17A+IL-10+ cells. Notably, cells 
producing IL-10 and/or IL-17A, including IFNIL-10+ but not IFNIL-10- cells, were 
refractory to the anti-proliferative effects of dexamethasone. This glucocorticoid-induced IL-
10 production was dependent on IL-2, which itself could independently upregulate IL-10. 
Higher doses of recombinant IL-2, whilst sustaining IL-10 production, inhibited the 
dexamethasone-induced IL-17A+ response.  
 
IL-10-producing Th17 cells are indicative of the non-pathogenic Th17 cell population that has 
been shown to have a critical role in restraining Th17 cell-mediated inflammatory and 
autoimmune diseases (25-27). This contrasts with pro-inflammatory IFNTh17 cells that have 
been implicated in both murine (21, 22) and human (23) pathologies. In addition to inducing 
IL-10+IL-17+ T cells, we show here that dexamethasone also induced IL-10+IL-22+ cells. Since 
Th17-associated cytokines play a central role in defence against extracellular infections at 
mucosal sites, we propose that in tissues such as the lung, the dual capacity of glucocorticoids 
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to both maintain at least certain anti-microbial defence mechanisms via IL-17A and IL-22, as 
well as dampen inflammation via IL-10, is highly desirable. It would therefore be interesting 
to study the co-production of these cytokines over the course of a range of diseases in humans; 
in mice IL-22 has been show to drive the initiation of airway inflammation but act as a negative 
regulator in established disease (35). We also observed that dexamethasone selectively 
enriched a population of IFNIL-10+ cells which we hypothesise would dampen excessive 
airway inflammation. Indeed, our earlier studies in steroid-refractory patients indicate that both 
IL-17A and IFN, but not IL-10, synthesis are significantly elevated compared to steroid-
sensitive patients (12). 
 
The capacity of dexamethasone to enhance the frequency of cells co-producing IL-10 with 
Th17-associated cytokines reflected preferential outgrowth of this population in culture and 
was dependent on the presence of the growth factor IL-2. Only the lower concentration of IL-
2 studied promoted the expansion of IL-17A+ or IL-17A+IL-10+ cells. Low-dose IL-2 is 
required for T cell proliferation and survival (31, 32), but increased IL-2 signalling is proposed 
to impair IL-17A responses as pSTAT5 is reported to compete with pSTAT3 for binding to the 
il17a gene locus (36, 37). Therefore, the fact that dexamethasone down regulated, but 
importantly did not eliminate expression of IL-2, IL-2Rα1, IL-2Rβ and pSTAT5 may favour 
the outgrowth of Th17 cells. However, we show that higher doses of IL-2 overcame this to 
inhibit dexamethasone-induced IL-17A although sustaining IL-10-producing cells. Hence our 
findings provide a novel approach to promoting non-pathogenic Th17 cells which co-produce 
IL-10. Of note, as well as driving the outgrowth of IL-10+ cells, the higher concentrations of 
rhIL-2 studied promoted the expansion of a population of cells that were predominantly 
negative for all cytokines assessed (data not shown), and may reflect a central memory T cell 
population (38).  
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The mechanisms by which dexamethasone increases the synthesis of IL-10 and IL-17A are 
likely to be distinct given the pleiotropic nature of glucocorticoid actions.  The relatively slow 
nature of both responses suggests that they are unlikely to be due to a dexamethasone-
glucocorticoid receptor complex binding directly to target DNA, although glucocorticoid 
response elements (GREs; consensus motif from Hocomoco, Jaspar, (39)) are located both up- 
and down-stream of the il10 promoter. GREs are also found within the vicinity of the il2, il2ra, 
il2rb and stat5 loci, suggesting that dexamethasone may directly influence the transcription of 
these genes. Increased production of Th17-associated cytokines may also be in part due to 
reduced Th1 and Th2 responses, both of which have been shown to reduce IL-17A production 
(40, 41). Using the same experimental system we previously reported that addition of IL-4 to 
the culture attenuated the IL-17A response (12). Conversely, neutralising IL-4, but not IFN, 
in culture increased levels of IL-17A in the control condition to levels comparable of 
dexamethasone-treated cells, which was unaffected by IL-4 blockade (data not shown).  
 
Minimal suppression by glucocorticoids of Th17 cell proliferation, as shown here, has also 
been observed in murine in vitro and in vivo systems when compared to Th1 and Th2 cells (18, 
42), and human pro-inflammatory Th17 cells have been shown to be refractory to 
dexamethasone’s suppressive effects on proliferation (23). One potential mechanism for this 
identified in this study is that cells co-producing IL-17A and IL-10 expressed elevated levels 
of CD25 which were refractory to inhibition by dexamethasone, in contrast to cells not making 
IL-10, enabling their preferential expansion. In line with this observation, it has been shown 
that only a subset of CD4+ T cells expressing elevated levels of CD25 continue to proliferate 
in the presence of dexamethasone, although cytokine expression was not assessed in that study 
(43). Our novel findings show that IL-10+ cells, irrespective of whether they co-produce pro-
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inflammatory cytokines, can maintain IL-2 signaling and proliferate in the presence of 
glucocorticoids.  
 
Our previous studies identify glucocorticoid-induced IL-17A as a feature of steroid-resistant 
severe asthma (12), but here we address the underlying mechanisms and single-cell 
phenotyping. Our data suggest that aberrant glucocorticoid-driven IL-17A in steroid-resistant 
asthma may be a result of the immune environment in these patients, and in particular low but 
not absent levels of IL-2.  Indeed, daily glucocorticoid therapy might dampen IL-2 receptor 
expression and signalling to favour Th17 differentiation and/or expansion, particularly in the 
setting of weak T cell stimulation, such as during sub-clinical airways infection with microbes 
such as Haemophilus, which is associated with severe asthma (44). To this end, severe 
asthmatics were found to have elevated soluble CD25 in circulation and increased expression 
by CD4+ T cells, which inversely correlated with airway obstruction (45, 46).  
 
Although not studied in asthma, low-dose IL-2 therapy has been found beneficial in patients 
with diseases including graft-versus-host disease (GVHD), many of whom were receiving 
glucocorticoids (47), and hepatitis C virus-induced vasculitis (48). Such beneficial effects may 
be due to IL-2 dampening Th17 cells, which is hypothesised to be beneficial in GVHD (49). 
However much of the research emphasis has been in describing the expansion of Foxp3+ Tregs 
following IL-2 therapy (47, 50, 51). Co-expression of Foxp3 and IL-10 was not assessed in this 
study but dexamethasone-driven IL-10 was not accompanied by a change in Foxp3 mRNA or 
protein expression (data not shown), suggesting that the cells in this study were not 
conventional Tregs. This is in line with both our own and independent reports (52-54) that 
observe very low levels of co-expression of Foxp3 and IL-10 protein in human CD4+ T cells. 
Our findings showing that IL-2 increases IL-10-producing memory CD4+ T cells may also 
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provide an explanation for the defective IL-10 production, but normal Foxp3 gene expression, 
in CD4+ T cells from a patient with CD25 deficiency manifesting as immune dysregulation, 
polyendocrinopathy, enteropathy and X-linked-like syndrome (55).  
 
We have previously shown that vitamin D can restore dexamethasone-induced IL-10 
production in severe asthma (10, 12), but  whether combining IL-2 therapy with glucocorticoids 
to further enhance IL-10 production and suppress IL-17A production is a pharmacotherapeutic 
option in severe asthma needs further consideration. Firstly, IL-17A, and other Th17-associated 
cytokines, have both beneficial and harmful actions.  Secondly, one of the main limitations to 
IL-2 therapies is the profound differences in immunologic effects of different IL-2 doses, with 
pro-inflammatory actions observed at the highest doses. Interestingly Sockolosky and 
colleagues (56) recently published on the generation of orthogonal IL-2 cytokine-receptor 
complexes that selectively target cell populations for adoptive cell therapy. Although the study 
did not measure its effects on levels of IL-10 and Th17-associated cytokines, they showed that 
IL-2, but not the orthogonal IL-2 complex increased the serum levels of several pro-
inflammatory cytokines in mice which is associated with serious side effects. It would therefore 
be interesting to investigate whether this may be a mechanism to therapeutically skew 
responses towards an IL-10-single-producing response, and any impact of common therapeutic 
agents such as glucocorticoids upon this process.   
 
In summary, we show that dexamethasone promotes the preferential proliferation of IL-10+ 
and IL-17A+ memory CD4+ T cells, specifically enriching for populations of cells co-producing 
IL-10 and multiple pro-inflammatory cytokines. Increasing the concentration of rhIL-2 in the 
presence of dexamethasone maintained elevated levels of IL-10 whilst reducing the IL-17A 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 20 
response, which may provide new avenues for the development of improved clinical therapies 
for asthma.  
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 21 
 
Acknowledgements 
EHM, LG, AOG and CMH designed the study and wrote the manuscript. EHM and LG 
performed experiments. PEP provided project guidance and helped with clinical sample 
collection. We thank the Flow Cytometry Science Technology Platform at The Francis Crick 
Institute and the research nurses at Guy’s Hospital. 
 
Conflicts of interest 
The authors declare no competing financial interests.  
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 22 
References 
1. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017. 
2. Oppong E, Cato AC. Effects of Glucocorticoids in the Immune System. Adv Exp Med Biol 
2015; 872: 217-233. 
3. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-
10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998; 85: 
122-130. 
4. John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, Barnes PJ, Chung KF. Inhaled 
corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-
1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release 
from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998; 157: 256-262. 
5. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, 
Coffman RL, Hawrylowicz CM, O'Garra A. In vitro generation of interleukin 10-
producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and 
inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195: 
603-616. 
6. Gupta A, Dimeloe S, Richards DF, Chambers ES, Black C, Urry Z, Ryanna K, Xystrakis E, 
Bush A, Saglani S, Hawrylowicz CM. Defective IL-10 expression and in vitro steroid-
induced IL-17A in paediatric severe therapy-resistant asthma. Thorax 2013. 
7. Nanzer AM, Chambers ES, Ryanna K, Richards DF, Black C, Timms PM, Martineau AR, 
Griffiths CJ, Corrigan CJ, Hawrylowicz CM. Enhanced production of IL-17A in patients 
with severe asthma is inhibited by 1α,25-dihydroxyvitamin D3 in a glucocorticoid-
independent fashion. J Allergy Clin Immunol 2013. 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 23 
8. Richards DF, Fernandez M, Caulfield J, Hawrylowicz CM. Glucocorticoids drive human 
CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-
5 and IL-13 production. Eur J Immunol 2000; 30: 2344-2354. 
9. Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T. A defect in corticosteroid-
induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic 
patients. J Allergy Clin Immunol. United States; 2002. p. 369-370. 
10. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon 
C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O'Garra A, Lavender P, Lee TH, 
Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting 
regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116: 146-
155. 
11. Barczyk A, Pierzchala W, Sozañska E. Interleukin-17 in sputum correlates with airway 
hyperresponsiveness to methacholine. Respir Med 2003; 97: 726-733. 
12. Chambers ES, Nanzer AM, Pfeffer PE, Richards DF, Timms PM, Martineau AR, Griffiths 
CJ, Corrigan CJ, Hawrylowicz CM. Distinct endotypes of steroid-resistant asthma 
characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of 
calcitriol. J Allergy Clin Immunol 2015. 
13. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL. IL-
17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and 
granulocytic influx? Respir Res 2006; 7: 135. 
14. Alyasin S, Karimi MH, Amin R, Babaei M, Darougar S. Interleukin-17 gene expression 
and serum levels in children with severe asthma. Iran J Immunol 2013; 10: 177-185. 
15. Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk 
factor for severe asthma. Respir Med 2010; 104: 1131-1137. 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 24 
16. Irvin C, Zafar I, Good J, Rollins D, Christianson C, Gorska MM, Martin RJ, Alam R. 
Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid 
characterizes a population of patients with severe asthma. J Allergy Clin Immunol 2014; 
134: 1175-1186.e1177. 
17. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J, Chakir J. 
IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to 
produce cytokines. J Allergy Clin Immunol 2001; 108: 430-438. 
18. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, 
Piganelli JD, Ray A, Kolls JK. TH17 cells mediate steroid-resistant airway inflammation 
and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-4097. 
19. Zhao J, Lloyd CM, Noble A. Th17 responses in chronic allergic airway inflammation 
abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. 
Mucosal Immunol 2013; 6: 335-346. 
20. Patel DD, Kuchroo VK. Th17 Cell Pathway in Human Immunity: Lessons from Genetics 
and Therapeutic Interventions. Immunity 2015; 43: 1040-1051. 
21. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei 
L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, 
Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ. Generation of pathogenic 
T(H)17 cells in the absence of TGF-β signalling. Nature 2010; 467: 967-971. 
22. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, 
Kunder S, Hafler DA, Sobel RA, Regev A, Kuchroo VK. Induction and molecular 
signature of pathogenic TH17 cells. Nat Immunol 2012; 13: 991-999. 
23. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, 
Abreu MT, Unutmaz D, Sundrud MS. Pro-inflammatory human Th17 cells selectively 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 25 
express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014; 211: 89-
104. 
24. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, 
Lanzavecchia A, Sallusto F. Pathogen-induced human TH17 cells produce IFN-gamma or 
IL-10 and are regulated by IL-1beta. Nature 2012; 484: 514-518. 
25. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua 
DJ. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain 
T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-1397. 
26. Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete 
MR, Licona-Limon P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, 
Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell 
RA. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. 
Nature 2015; 523: 221-225. 
27. Noster R, de Koning HD, Maier E, Prelog M, Lainka E, Zielinski CE. Dysregulation of 
proinflammatory versus anti-inflammatory human TH17 cell functionalities in the 
autoinflammatory Schnitzler syndrome. J Allergy Clin Immunol 2016; 138: 1161-1169 
e1166. 
28. Gabrysova L, Howes A, Saraiva M, O'Garra A. The regulation of IL-10 expression. Curr 
Top Microbiol Immunol 2014; 380: 157-190. 
29. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei 
L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, 
Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ. Generation of pathogenic 
T(H)17 cells in the absence of TGF-beta signalling. Nature 2010; 467: 967-971. 
30. Nowell PC. Inhibition of human leukocyte mitosis by prednisolone in vitro. Cancer Res 
1961; 21: 1518-1521. 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 26 
31. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, 
Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and 
inhibited by IL-27/STAT1. Nat Med 2007; 13: 711-718. 
32. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN. Stat5 activation is uniquely associated 
with cytokine signaling in peripheral T cells. Immunity 1999; 11: 225-230. 
33. Boumpas DT, Anastassiou ED, Older SA, Tsokos GC, Nelson DL, Balow JE. 
Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression 
in vitro at the level of nuclear transcription. J Clin Invest 1991; 87: 1739-1747. 
34. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS. Resident memory 
T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. 
PLoS One 2011; 6: e16245. 
35. Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht B, Teixeira MM, 
Charron S, Fick L, Erard F, Warszawska K, Wolk K, Quesniaux V, Ryffel B, Togbe D. 
Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J 
Respir Crit Care Med 2011; 183: 1153-1163. 
36. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel 
R, Hennighausen L, Shevach EM, O'Shea J J. Interleukin-2 signaling via STAT5 
constrains T helper 17 cell generation. Immunity 2007; 26: 371-381. 
37. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, 
Hirahara K, Sun HW, Wei L, Vahedi G, Kanno Y, O'Shea JJ, Laurence A. Opposing 
regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and 
STAT5. Nat Immunol 2011; 12: 247-254. 
38. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat 
Immunol 2011; 12: 467-471. 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 27 
39. Schone S, Jurk M, Helabad MB, Dror I, Lebars I, Kieffer B, Imhof P, Rohs R, Vingron M, 
Thomas-Chollier M, Meijsing SH. Corrigendum: Sequences flanking the core-binding site 
modulate glucocorticoid receptor structure and activity. Nature communications 2016; 7: 
13784. 
40. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. 
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T 
helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132. 
41. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and 
regulatory T cells. Nature 2006; 441: 235-238. 
42. Schewitz-Bowers LP, Lait PJ, Copland DA, Chen P, Wu W, Dhanda AD, Vistica BP, 
Williams EL, Liu B, Jawad S, Li Z, Tucker W, Hirani S, Wakabayashi Y, Zhu J, Sen N, 
Conway-Campbell BL, Gery I, Dick AD, Wei L, Nussenblatt RB, Lee RW. 
Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proc 
Natl Acad Sci U S A 2015; 112: 4080-4085. 
43. Lee RW, Creed TJ, Schewitz LP, Newcomb PV, Nicholson LB, Dick AD, Dayan CM. 
CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with 
glucocorticoids. J Immunol 2007; 179: 7941-7948. 
44. Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, 
Hugenholtz P, Willner D, Gibson PG. Airway dysbiosis: Haemophilus influenzae and 
Tropheryma in poorly controlled asthma. Eur Respir J 2016; 47: 792-800. 
45. Corrigan CJ, Brown PH, Barnes NC, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance 
in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T 
lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. The American review 
of respiratory disease 1991; 144: 1026-1032. 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 28 
46. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma. Relationship 
to disease severity and atopic status. The American review of respiratory disease 1990; 
141: 970-977. 
47. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, Armand P, 
Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan 
DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host 
disease. N Engl J Med 2011; 365: 2055-2066. 
48. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, 
Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced 
vasculitis. N Engl J Med 2011; 365: 2067-2077. 
49. Malard F, Gaugler B, Lamarthee B, Mohty M. Translational opportunities for targeting the 
Th17 axis in acute graft-vs.-host disease. Mucosal Immunol 2016; 9: 299-308. 
50. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler 
C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J. Low-dose 
interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-
versus-host disease. Sci Transl Med 2013; 5: 179ra143. 
51. Rosenzwajg M, Churlaud G, Mallone R, Six A, Derian N, Chaara W, Lorenzon R, Long 
SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, 
Klatzmann D. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned 
milieu in T1D patients. Journal of autoimmunity 2015; 58: 48-58. 
52. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur 
J Immunol 2008; 38: 925-927. 
53. Passerini L, Di Nunzio S, Gregori S, Gambineri E, Cecconi M, Seidel MG, Cazzola G, 
Perroni L, Tommasini A, Vignola S, Guidi L, Roncarolo MG, Bacchetta R. Functional 
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 29 
type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX 
syndrome. Eur J Immunol 2011; 41: 1120-1131. 
54. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabryšová L, Christensen J, 
Gupta A, Saglani S, Bush A, O'Garra A, Brown Z, Hawrylowicz CM. The role of 1α,25-
dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ 
T cells. Eur J Immunol 2012; 42: 2697-2708. 
55. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and 
defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119: 
482-487. 
56. Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George 
BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone 
JA, Garcia KC. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-
receptor complexes. Science 2018; 359: 1037-1042. 
  
JI ID: 18-00697-FL: Glucocorticoid-driven IL-10 is IL-2-dependent 
 30 
Figure legends 
 
Figure 1: Glucocorticoids enhance production of IL-10 in memory CD4+ T cells.  
PBMCs (A and B) or memory CD4+ T cells (C) from healthy donors were stimulated with 10-
9M-10-7M dexamethasone or control for 5 days. Cells were then stimulated for 4 hours with 
PMA and Ionomycin prior to staining for surface markers and intracellular IL-10. For PBMC 
cultures, shown are representative plots (A) and cumulative data (B) gating of CD4+CD45RO+ 
cells (n=4); data assessed data assessed by a paired t-test. C, the percentage of IL-10+ cells in 
memory CD4+ T cell cultures (n=9); data assessed by repeated measures one-way ANOVA 
with Tukey’s multiple comparisons test. * p ≤ 0.05, **** p ≤ 0.0001. 
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Figure 2: Glucocorticoids increase expression of IL-10 and IL-17A, but not IFN, IL-4 or 
IL-2, in memory CD4+ T cell cultures 
Memory CD4+ T cells were stimulated in the presence of vehicle control (grey) or 10-7M 
dexamethasone (black). On the indicated day, cells were stimulated for 4 hours with PMA and 
Ionomycin to assess intracellular cytokine expression. Shown are cumulative data (A; n=4 
except IL-4, n=2) and representative plots (B). Data assessed by a two-way ANOVA with 
Sidak’s multiple comparisons test; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Figure 3: Co-production of IL-10 and pro-inflammatory cytokines is induced by 
glucocorticoids in memory CD4+ T cells 
Memory CD4+ T cells were stimulated in the presence of vehicle control or 10-7M 
dexamethasone. On day 5 cells were stimulated for 4 hours with PMA and Ionomycin prior to 
performing intracellular cytokine staining. A, representative contour plots. B, the total (black) 
percentage of cells producing the indicated cytokine alongside those co-expressing IL-10 (red) 
or the IL-10- counterparts (blue); data assessed by two-way ANOVA with Sidak’s multiple 
comparison’s test (IL-10 n=32; IL-17A n=29; IL-17F n=7; IL-22 n=6; IFN n=25; IL-4 n=6; 
IL-2 n=19). C, representative overlay dot plots identifying which cells within the IL-10/IL-
17A plots (black; far left) co-produced the indicated cytokine in colour (IL-17F in yellow, IL-
22 in red, IFN in blue and IL-4 in green). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001.  
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Figure 4: IL-17A+ cells and cells co-producing IL-10 are refractory to the suppressive 
effects of glucocorticoids on cell proliferation 
Memory CD4+ T cells were labelled with CellTrace Violet on day 0 and then stimulated in the 
presence of vehicle control (white) or in the presence of 10-7M dexamethasone (grey). On day 
5 cells were stimulated for 4 hours with PMA and Ionomycin prior to performing intracellular 
cytokine staining. A, representative plots showing expression of cytokines relative to cell 
proliferation. B, cumulative data of the percentage of cells expressing the indicated cytokine 
within the divided or undivided cell population; data assessed by a two-way ANOVA with 
Sidak’s multiple comparisons test. C, representative histograms showing the proliferation of 
cells when gating on the indicated cytokine-expressing populations, alongside cumulative data 
(D); data assessed by a paired t-test. IL-17A and IL-10 n=9; IFN/IL-2 n=7; IL-4 n=6; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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Figure 5: Glucocorticoids dampen IL-2 signalling in memory CD4+ T cells 
Memory CD4+ T cells were stimulated in the presence of vehicle control (whit) or 10-7M 
dexamethasone (grey). A and B, after the indicated length of time, cells were surface stained 
for CD25 (IL-2Ra; top) and CD122 (IL-2Rb; middle); for phospho-STAT5 staining, cells were 
rested for 2 hours, stimulated with 5ng/ml rhIL-2 for 30 minutes and then phospho-STAT5 
expression assessed. Shown are representative overlay histograms (A) alongside cumulative 
data for the mean fluorescence intensity and the percentage of positive cells (B; n=4). C, 
representative plots showing expression of CD25 by cells relative to their proliferation status 
(Cell Trace violet) on day 5. D, on day 5 cells were stimulated for 4 hours with PMA and 
Ionomycin prior to surface CD25 and intracellular cytokine staining (n=3); shown is the % of 
CD25+ cells when gating on all cells (left) or the indicated cytokine-expressing populations 
(n=3). Data assessed by a two-way ANOVA with Sidak’s multiple comparisons test; ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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Figure 6: High dose IL-2 in the context of glucocorticoid induces maximal IL-10 
production whilst inhibiting IL-17A in memory CD4+ T cells 
Memory CD4+ T cells were stimulated with anti-CD3 alone (0 IU/ml rhIL-2), plus 10 mg/ml 
neutralising anti-IL-2 (aIL-2) or in the presence of the indicated concentration of rhIL-2 (50, 
500 or 1000 IU/ml) in the presence of vehicle control (white bars) or 10-7M dexamethasone 
(grey bars). On day 5 cells were stimulated for 4 hours with PMA and Ionomycin prior to 
performing intracellular cytokine staining. A, the percentage of cells expressing the indicated 
cytokine(s). B, representative plots showing expression of IL-10 relative to cell proliferation 
over the IL-2 titration C, the percentage of IL-10+ cells when gating on the divided (top) or 
undivided (bottom) cells. n=6; ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between control 
and dexamethasone; # p ≤ 0.05 and ## p ≤ 0.01 between different IL-2 doses.   
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